DS

Daiichi Sankyo

China - Shanghai
Biotechnology1 H-1B visas (FY2023)
WebsiteLinkedInCareers Page

Focus: Small Molecules

Daiichi Sankyo is a life sciences company focused on Small Molecules.

OncologyCardiovascularMetabolic DiseasesNeurologyImmunology
Funding Stage
PUBLIC
Open Jobs
0

Products & Portfolio (6)

4 discontinued products not shown

DATROWAY
datopotamab deruxtecan-dlnk
Launch
ADCINJECTION · INJECTABLE
deruxtecan-dlnk, is a Trop-2-directed antibody-drug conjugate. The antibody is a humanized anti-Trop2 IgG1. The small molecule, DXd, is a topoisomerase I inhibitor attached to the antibody by a cleavable linker. Following binding to Trop-2 on cells, including tumor cells, datopotamab deruxtecan-dlnk undergoes internalization and intracellular linker cleavage by lysosomal enzymes. Upon release, the membrane-permeable DXd causes DNA damage and apoptotic cell death. Datopotamab deruxtecan-dlnk had anti-tumor activity in mouse models of lung cancer including EGFR-mutated and breast cancer.
metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC)platinum-based chemotherapymetastatic+8 more
2025
30
DATROWAY
datopotamab deruxtecan
Growth
ADCIV (INFUSION) · INJECTABLE
deruxtecan-dlnk, is a Trop-2-directed antibody-drug conjugate. The antibody is a humanized anti-Trop2 IgG1. The small molecule, DXd, is a topoisomerase I inhibitor attached to the antibody by a cleavable linker. Following binding to Trop-2 on cells, including tumor cells, datopotamab deruxtecan-dlnk undergoes internalization and intracellular linker cleavage by lysosomal enzymes. Upon release, the membrane-permeable DXd causes DNA damage and apoptotic cell death. Datopotamab deruxtecan-dlnk had anti-tumor activity in mouse models of lung cancer including EGFR-mutated and breast cancer.
metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC)platinum-based chemotherapymetastatic+8 more
2025
30
ENHERTU
fam-trastuzumab deruxtecan-nxki
Peak
ADCINJECTION · INJECTABLE
Fam-trastuzumab deruxtecan-nxki is a HER2-directed antibody-drug conjugate. The antibody is a humanized anti-HER2 IgG1. The small molecule, DXd, is a topoisomerase I inhibitor attached to the antibody by a cleavable linker. Following binding to HER2 on tumor cells, fam-trastuzumab deruxtecan-nxki undergoes internalization and intracellular linker cleavage by lysosomal enzymes. Upon release, the membrane-permeable DXd causes DNA damage and apoptotic cell death.
metastatic HER2-positive (IHC 3+the neoadjuvantadjuvant setting+13 more
2019
30
SAVAYSA
edoxaban tosylate
LOE Approaching
ORAL · TABLET
FXa. It does not require antithrombin III for antithrombotic activity. Edoxaban inhibits free FXa, and prothrombinase activity and inhibits thrombin-induced platelet aggregation. Inhibition of FXa in the coagulation cascade reduces thrombin generation and reduces thrombus formation.
deep vein thrombosis (DVT)pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant () 1pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant+2 more
2015
15
TURALIO
pexidartinib hydrochloride
Peak
ORAL · CAPSULE
1 receptor (CSF1R), KIT proto-oncogene receptor tyrosine kinase (KIT), and FMS-like tyrosine kinase 3 (FLT3) harboring an internal tandem duplication (ITD) mutation. Overexpression of the CSF1R ligand promotes cell proliferation and accumulation in the synovium. In vitro, pexidartinib inhibited proliferation of cell lines dependent on CSF1R and ligand-induced autophosphorylation of CSF1R. Pexidartinib also inhibited the proliferation of a CSF1R dependent cell line in vivo.
functional limitationsnot amenable to improvement with surgery
2019
0
VANFLYTA
quizartinib
Growth
ORAL · TABLET
FLT3. Quizartinib and its major active metabolite AC886 bind to the adenosine triphosphate (ATP) binding domain of FLT3 with comparable affinity, and both had 10-fold lower affinity towards FLT3-ITD mutation compared to FLT3 in a binding assay. Quizartinib and AC886 inhibited FLT3 kinase activity, preventing autophosphorylation of the receptor, thereby inhibiting downstream FLT3 receptor signaling and blocking FLT3-ITD-dependent cell proliferation. Quizartinib showed antitumor activity in a mouse model of FLT3-ITD-dependent leukemia.
combination with standard cytarabineanthracycline inductioncytarabine consolidation+2 more
2023
0

Pipeline & Clinical Trials

Archival tissue specimen and immunohistochemistry staining
Non-small Cell Lung Cancer
N/A
Clinical Trials (1)
NCT05769764A Study of Prevalence of HER3 Expression in Non-Small Cell Lung Cancer
N/A
Addressing Real-world Anticoagulant Management Issues in Stroke
Stroke
N/A
not applicable
Ischemic Stroke
N/A
Trastuzumab deruxtecan
HER2-positive Gastric Cancer
N/A
Clinical Trials (5)
NCT06819007Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Phase 3
NCT03523585DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
Phase 3
NCT05950945Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Phase 3

+2 more

TAXUS Liberté Paclitaxel-Eluting Coronary Stent
Coronary Artery Disease
N/A
Clinical Trials (1)
NCT00997503TAXUS Libertē Post Approval Study
N/A
Villalta phone score > or = to 5
Post Thrombotic Syndrome
N/A
Clinical Trials (1)
NCT03054727Long Term Assessment of Post Thrombotic Syndrome : OPTIMEV Study ( SPOT )
N/A
N/A
Clinical Trials (1)
NCT04165798KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
N/A
Trastuzumab deruxtecan
Unresectable Breast Cancer
N/A
Clinical Trials (1)
NCT05945732DESTINY Breast Respond HER2-low Europe
N/A
Non Interventional
Pseudoxanthoma Elasticum
N/A
Clinical Trials (1)
NCT05025722Pseudoxanthoma Elasticum (PXE) Natural History Biomarkers in PXE Individuals and Their Biological Non-PXE Siblings
N/A
N/A
Clinical Trials (2)
NCT01496885Observational Study to Evaluate the Simplified-STroke REhabilitation Assessment of Movement (S-STREAM) Scale in Subjects Who Have Experienced a Nonhemorrhagic Ischemic Stroke
N/A
NCT05486351Keeping Oral o Parental AnticoaguLation in the Acute Phase of Cardioembolic Ischemic Stroke
N/A
IMPROVE Stroke Care- Developing and Optimizing Regional Systems of Stroke Care
Acute Stroke
N/A
Clinical Trials (1)
NCT04242784IMPROVE Stroke Care- Developing and Optimizing Regional Systems of Stroke Care
N/A
N/A
Clinical Trials (1)
NCT02950168Edoxaban Management in Diagnostic and Therapeutic Procedures
N/A
ImplemeNtation oF demOnstration pRoject for Health systeMs: Atrial Fibrillation (INFORM-AF) Part 1
Atrial Fibrillation
N/A
N/A
Clinical Trials (2)
NCT06975371Real-World Outcomes of Patients With Metastatic Breast Cancer After Treatment With First-Line ET+CDK4/6i
N/A
NCT06585501A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China
N/A
N/A
Clinical Trials (1)
NCT06099639Medical Access Program for Patritumab Deruxtecan
N/A
N/A
Clinical Trials (1)
NCT04594915Evaluation of Treatment Safety in Patients With Atrial Fibrillation on Edoxaban Therapy in Real-Life in Turkey
N/A
N/A
Clinical Trials (1)
NCT05804747A Study to Evaluate Effectiveness and Safety of Edoxaban in Patients 80 Years of Age or Older With Nonvalvular Atrial Fibrillation
N/A
N/A
Clinical Trials (1)
NCT00122447Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance
N/A
N/A
Clinical Trials (1)
NCT01040312An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors
N/A
N/A
Clinical Trials (1)
NCT04747496Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China
N/A
Metastatic Breast Cancer in Austria
Breast Cancer
N/A
Clinical Trials (1)
NCT03870620Metastatic Breast Cancer in Austria
N/A
N/A
Clinical Trials (1)
NCT06809764Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
N/A
N/A
Clinical Trials (1)
NCT07092254Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer
N/A
N/A
Clinical Trials (1)
NCT00938405Efficacy of Colesevelam in Subjects With Type 1 Diabetes Mellitus
N/A
A Study to Investigate the Prevalence of Human Epidermal Growth Factor Receptor 2 (HER2) Immunohisto
Cervical Cancers
N/A
Clinical Trials (1)
NCT06925113A Study to Investigate the Prevalence of Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ and Characterize the Clinicopathologic Features of Gynecologic Cancers in Taiwan
N/A
N/A
Clinical Trials (1)
NCT01973569AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Participants With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment
N/A
Computer Electronic Alert
Atrial Fibrillation
N/A
Clinical Trials (1)
NCT02339493Electronic Alerts for Stroke Prevention in Patients With Atrial Fibrillation or Atrial Flutter
N/A
Bempedoic acid and/or its fixed dose combination with ezetimibe
Primary Hypercholesterolemia
N/A
Clinical Trials (1)
NCT05798390Treatment With Bempedoic Acid And/Or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia Or Mixed Dyslipidemia
N/A
N/A
Clinical Trials (1)
NCT00476710Effects of Colesevelam HCl On Bile Acid Kinetics
N/A
N/A
Clinical Trials (3)
NCT07474649A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events
Phase 3
NCT06686615A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
N/A
NCT04579367Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia
N/A
N/A
Clinical Trials (1)
NCT06546202Real-World Pharmacological Treatment Pattern of Neuropathic Pain in China
N/A
N/A
Clinical Trials (1)
NCT04807595Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status
N/A
Trastuzumab deruxtecan
HER2-positive Breast Cancer
N/A
Clinical Trials (1)
NCT05458401EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan
N/A
N/A
Clinical Trials (1)
NCT02448901Influence of Edoxaban on Coagulability and Thrombin Generation: An in Vitro Study Focusing on Thrombelastography
N/A
N/A
Clinical Trials (1)
NCT02952599Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Korea and Taiwan (ETNA-VTE-KOR-TWN)
N/A
CPT-11 based regimens
Metastatic Colorectal Cancer
N/A
Clinical Trials (1)
NCT01039506An Observational Study of CPT-11 Based Regimens and UGT1A1 Genotypes in Metastatic Colorectal Cancer (mCRC)
N/A
Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)
Lung Cancer
N/A
N/A
N/A
Clinical Trials (1)
NCT02944019Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation
N/A
Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008
Metastatic Breast Cancer
N/A
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
Bladder Cancer
N/A
Clinical Trials (1)
NCT06973161ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
N/A
mgt of bleeding concerns/complications of oral anticoagulants
Blood Coagulation
N/A
Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project
Giant Cell Tumors
N/A
Clinical Trials (1)
NCT02948088Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project
N/A
Standard therapy of Alzheimer Dementia
Alzheimer Dementia
N/A
Clinical Trials (1)
NCT02267486Exploratory Study for the Validity of QuQu Scale
N/A
Evaluation of Oral Anticoagulation With Vitamin K Antagonists - The thrombEVAL Study Programme
Anticoagulant Antagonists, Vitamin K and Other Coagulants Causing Adverse Effects in Therapeutic Use
N/A
Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition
Percutaneous Coronary Intervention
N/A
Clinical Trials (1)
NCT01582217Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition
N/A
Exercise bout
Healthy
N/A
Clinical Trials (1)
NCT02565823The Effects of Exercise of Secreted Factors From Muscle and Adipose Tissue
N/A
Trastuzumab deruxtecan
HER2-positive Breast Cancer
N/A
Clinical Trials (1)
NCT06210776A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
N/A
Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally
Gastric Cancer
N/A
Clinical Trials (1)
NCT05606094Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East Asia
N/A
Combination of bempedoic acid and ezetimibe
Primary Hypercholesterolaemia
N/A
Clinical Trials (1)
NCT07206472A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia
N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 10 approved products, 147 clinical trials
Top TAs: Oncology, Cardiovascular, Metabolic Diseases
H-1B (2023): 1 approval
Portfolio Health
Launch1 (10%)
Growth2 (20%)
Peak2 (20%)
LOE Approaching5 (50%)
10 total products
Therapeutic Area Focus
Oncology
4 marketed293 pipeline
Cardiovascular
1 marketed129 pipeline
Neurology
1 marketed29 pipeline
Respiratory
1 marketed10 pipeline
Nephrology
9 pipeline
Immunology
9 pipeline
Marketed
Pipeline

Hiring Trend

Stable
0
Open Roles
+0
Added
-0
Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub